New Gene Discovery Offers Hope for Ulcerative Colitis Treatment

Scientists have identified a new gene, OTUD3, linked to ulcerative colitis, an inflammatory bowel condition. This discovery offers potential pathways for new treatments.

A Brisbane family, with five members across three generations diagnosed with ulcerative colitis, contributed significantly to the research.

The condition caused severe symptoms for the family, leading to surgery for four members, including one at age 14, to remove all or part of their bowels.

Gene Discovery Details

Researchers utilized advanced genomic sequencing, comparing DNA from affected and unaffected family members, to pinpoint a mutation in the OTUD3 gene.

Dr. Rabina Giri, lead researcher from Mater Research's Inflammatory Bowel Disease Group, stated that this study is the first to connect the OTUD3 gene with intestinal health. Previously, the gene was known for its role in cancer biology. The research indicates that OTUD3 is crucial for maintaining the gut lining's integrity, and its disruption leads to inflammation.

Prevalence and Function

The OTUD3 mutation was found not only in the Brisbane family but also in a significant number of other ulcerative colitis patients, based on data from UK and Finnish biobanks. Additionally, OTUD3 dysfunction was observed in other patients without the specific mutation, though the exact reasons are still being investigated.

The OTUD3 gene provides instructions for producing a protein vital for the gut's protective barrier. A failure in this barrier can allow bacteria to invade the gut lining, triggering chronic inflammation.

Future Research and Impact

The findings suggest potential for developing new drugs that could "upregulate" the expression of the protein produced by OTUD3, potentially offering a treatment strategy. Preliminary data indicates some existing drugs may already increase this expression.

Scientists are seeking further funding to explore the use of drugs for other conditions as treatments for ulcerative colitis and to investigate environmental factors, such as high-sugar Western diets, that might trigger the disease in genetically susceptible individuals. Approximately 0.1 percent of people of South Asian descent carry the OTUD3 mutation.

Early diagnosis and treatment with anti-tumour necrosis factor (TNF) drugs in a young member of the Brisbane family prevented the need for bowel removal, stabilizing his condition since 2021.

Expert Perspectives

Gastroenterologist Jake Begun, who leads Mater Research's Inflammatory Bowel Disease Research Group, noted the study's importance in uncovering chronic disease causes and opening doors for new diagnostic tools and therapies targeting gut linings. Professor Albert Lam of Griffith University described the discovery as significant for understanding the bowel barrier and guiding more effective therapies.

Over 100,000 Australians are estimated to be living with inflammatory bowel disease. The study was published in the journal "Cellular and Molecular Gastroenterology and Hepatology."